Henry Schein, US42548G1040

Henry Schein stock gains support from Piper Sandler target hike

Published on 09/18/2026 at 19:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Henry Schein stock is backed by a fresh Piper Sandler Buy rating, with the target price raised to USD 104 as of September 18, 2026. Valuation metrics also point to an undervalued profile compared with its industry peers.

Isometrische 3D-Illustration der Lieferkette von Medizinprodukten von Produktion zu Klinik
Henry Schein US42548G1040 Wertschöpfungskette vom Hersteller über Lager bis zur Zahnarztpraxis isometrisch dargestellt, Illustration mit AI erstellt.

Henry Schein Inc. stock (ISIN US42548G1040) was recently trading near USD 85 on Nasdaq on September 18, 2026, after a modest pullback from earlier in the week, while a new analyst target hike and favorable valuation metrics have come into focus for investors.

Piper Sandler raises target on Henry Schein stock

According to Futunn on September 18, 2026, Piper Sandler analyst Jason Bednar has maintained Henry Schein stock at Buy and lifted his target price from USD 95 to USD 104, signaling increased conviction in the company’s earnings outlook.

The new USD 104 target implies a noticeable upside from the recent Nasdaq close around USD 85, whereas the previous USD 95 target had pointed to a smaller potential gain based on similar price levels. For investors, the revision underlines that at least one covering analyst now sees more room for appreciation if Henry Schein delivers on its profit trajectory.

Valuation points to potential undervaluation

As Yahoo Finance reported on September 18, 2026, Henry Schein carries a forward price-earnings ratio of 13.27, compared with an industry average P/E of 17.36, and a price-sales ratio of 0.7 versus an industry average P/S of 1.71.

Based on the same overview, Henry Schein’s price-book ratio stands at 2.01, and its price-cash-flow ratio at 11.89, which together feed into a Value grade of A and a Zacks Rank of Buy, suggesting that the stock is trading at a discount relative to peers despite a solid earnings backdrop.

The valuation metrics mean that at current price levels around USD 85, investors are paying materially less for each dollar of expected earnings and sales than the typical company in Henry Schein’s sector. That gap between Henry Schein’s 13.27 forward P/E and the industry’s 17.36 ratio — more than 4 full turns — is one of the reasons the stock is being characterized as undervalued by the cited analysis.

Earnings outlook and recent price action

The same valuation review notes that Henry Schein’s forward P/E over the past 52 weeks has ranged from 12.57 to 15.82, with a median near 13.90, indicating that the current multiple of 13.27 sits close to the middle of its recent band and below the sector average, even after the latest analyst target increase.Yahoo Finance

According to the same article, Henry Schein also shows a PEG ratio — price-earnings-growth — of 2.11 compared with an industry average PEG of 2.21, with its own PEG in the past year fluctuating between 1.77 and 2.31 and a median of 2.08.Yahoo Finance This slight discount on the PEG metric reinforces the picture of a stock whose valuation does not fully reflect its earnings growth profile.

On the price side, a quote overview from Davy Select shows Henry Schein at USD 85.04 as of September 18, 2026, 2:39 p.m. local time, with an intraday loss of 1.99% and a trading range between USD 87.10 and USD 84.15 on the same day.Davy Select The day’s move follows a prior closing level of USD 86.77 on September 16, 2026 highlighted in a Reuters metrics overview, indicating a modest pullback of roughly USD 1.73 from that earlier reference.Reuters

The same Davy Select snapshot lists Henry Schein’s day high and low at USD 87.10 and USD 84.15, respectively, underscoring that the stock remains volatile within its intraday band but broadly aligned with valuation measures that point to room for upside if sentiment improves.Davy Select

Risk considerations for investors

While the valuation signals and the Piper Sandler target hike support a constructive view on Henry Schein stock, the Zacks-based analysis also stresses that earnings expectations need to be met for the undervaluation thesis to play out.Yahoo Finance If earnings growth were to slow or margins come under pressure, the discount relative to peers could narrow without significant share price gains.

Moreover, the sector comparison shows that Henry Schein’s PEG and other ratios are not dramatically lower than the industry, but rather moderately below average, so a deterioration in the operating environment or competitive dynamics could quickly erode the perceived valuation advantage.

Henry Schein stock price as of latest trading

Henry Schein stock most recently changed hands at USD 85.04 on Nasdaq on September 18, 2026, at 2:39 p.m., down 1.99% from the prior close, with the day’s trading range between USD 87.10 and USD 84.15.

Henry Schein stock at a glance

  • Company: Henry Schein Inc.
  • ISIN: US42548G1040
  • Ticker: HSIC
  • Trading venue: Nasdaq
  • Price (as of September 18, 2026, 14:39): 85.04 USD
  • Sector / Industry: Health care supplies and distribution
  • Index membership: S&P 500

More news and analyses on Henry Schein stock

Disclaimer...

en | US42548G1040 | HENRY SCHEIN | boerse | 70127165 | bgmi